25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Sanofi
Buy, Hold or Sell?

Let's analyze Sanofi together

I guess you are interested in Sanofi. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sanofi. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Sanofi

I send you an email if I find something interesting about Sanofi.

1. Quick Overview

1.1. Quick analysis of Sanofi (30 sec.)










1.2. What can you expect buying and holding a share of Sanofi? (30 sec.)

How much money do you get?

How much money do you get?
$14.78
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
$61.68
Expected worth in 1 year
$64.56
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
$17.67
Return On Investment
18.5%

For what price can you sell your share?

Current Price per Share
$95.50
Expected price per share
$87.72 - $112.05
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Sanofi (5 min.)




Live pricePrice per Share (EOD)
$95.50
Intrinsic Value Per Share
$42.86 - $81.65
Total Value Per Share
$104.54 - $143.33

2.2. Growth of Sanofi (5 min.)




Is Sanofi growing?

Current yearPrevious yearGrowGrow %
How rich?$77.4b$76.6b$876.4m1.1%

How much money is Sanofi making?

Current yearPrevious yearGrowGrow %
Making money$5.6b$8.7b-$3b-55.0%
Net Profit Margin12.5%18.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Sanofi (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Sanofi?

Welcome investor! Sanofi's management wants to use your money to grow the business. In return you get a share of Sanofi.

First you should know what it really means to hold a share of Sanofi. And how you can make/lose money.

Speculation

The Price per Share of Sanofi is $95.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sanofi.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sanofi, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $61.68. Based on the TTM, the Book Value Change Per Share is $0.72 per quarter. Based on the YOY, the Book Value Change Per Share is $3.76 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $3.69 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sanofi.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps4.484.7%4.484.7%6.947.3%5.816.1%5.115.4%
Usd Book Value Change Per Share0.720.8%0.720.8%3.763.9%2.532.7%1.731.8%
Usd Dividend Per Share3.693.9%3.693.9%3.463.6%3.383.5%3.193.3%
Usd Total Gains Per Share4.424.6%4.424.6%7.227.6%5.916.2%4.925.2%
Usd Price Per Share99.61-99.61-96.28-95.89-89.41-
Price to Earnings Ratio22.24-22.24-13.87-21.16-20.53-
Price-to-Total Gains Ratio22.55-22.55-13.34-18.39-20.38-
Price to Book Ratio1.62-1.62-1.58-1.72-1.75-
Price-to-Total Gains Ratio22.55-22.55-13.34-18.39-20.38-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share95.5
Number of shares10
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share3.693.38
Usd Book Value Change Per Share0.722.53
Usd Total Gains Per Share4.425.91
Gains per Quarter (10 shares)44.1759.13
Gains per Year (10 shares)176.66236.53
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
114829167135101227
229658344270203464
344387521406304701
4591116698541405938
57391448756765061175
688717310528116081412
7103520212299477091649
81182231140610828101886
91330260158312179112123
1014782891760135210132360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%24.01.00.096.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%8.02.00.080.0%20.05.00.080.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%25.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%25.00.00.0100.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Sanofi compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.7220.7220%3.761-81%2.532-71%1.730-58%
Book Value Per Share--61.67761.6770%60.955+1%56.211+10%51.441+20%
Current Ratio--1.2671.2670%1.423-11%1.460-13%1.583-20%
Debt To Asset Ratio--0.4120.4120%0.410+1%0.434-5%0.436-6%
Debt To Equity Ratio--0.7040.7040%0.698+1%0.775-9%0.779-10%
Dividend Per Share--3.6953.6950%3.456+7%3.381+9%3.191+16%
Eps--4.4794.4790%6.941-35%5.806-23%5.115-12%
Free Cash Flow Per Share--5.8115.8110%6.903-16%5.8130%5.077+14%
Free Cash Flow To Equity Per Share---0.866-0.8660%2.076-142%0.575-251%1.115-178%
Gross Profit Margin--1.0001.0000%1.0000%0.143+600%-0.405+140%
Intrinsic Value_10Y_max--81.652--------
Intrinsic Value_10Y_min--42.864--------
Intrinsic Value_1Y_max--6.941--------
Intrinsic Value_1Y_min--4.930--------
Intrinsic Value_3Y_max--21.800--------
Intrinsic Value_3Y_min--14.351--------
Intrinsic Value_5Y_max--37.800--------
Intrinsic Value_5Y_min--23.193--------
Market Cap119716893056.000-5%125150004000.000125150004000.0000%121008047500.000+3%120595189122.000+4%113975870711.000+10%
Net Profit Margin--0.1250.1250%0.184-32%0.174-28%0.161-22%
Operating Margin--0.2130.2130%0.222-4%0.202+6%0.204+5%
Operating Ratio--0.7870.7870%0.738+7%0.778+1%0.7890%
Pb Ratio1.548-4%1.6151.6150%1.579+2%1.717-6%1.749-8%
Pe Ratio21.320-4%22.23822.2380%13.870+60%21.157+5%20.535+8%
Price Per Share95.500-4%99.61099.6100%96.275+3%95.889+4%89.412+11%
Price To Free Cash Flow Ratio16.435-4%17.14217.1420%13.947+23%17.014+1%18.390-7%
Price To Total Gains Ratio21.623-4%22.55422.5540%13.340+69%18.395+23%20.381+11%
Quick Ratio--0.8270.8270%0.575+44%0.753+10%0.931-11%
Return On Assets--0.0430.0430%0.067-36%0.059-27%0.055-22%
Return On Equity--0.0730.0730%0.114-36%0.104-30%0.097-25%
Total Gains Per Share--4.4174.4170%7.217-39%5.913-25%4.921-10%
Usd Book Value--77490696600.00077490696600.0000%76614206400.000+1%70692634440.000+10%65517486120.000+18%
Usd Book Value Change Per Share--0.7220.7220%3.761-81%2.532-71%1.730-58%
Usd Book Value Per Share--61.67761.6770%60.955+1%56.211+10%51.441+20%
Usd Dividend Per Share--3.6953.6950%3.456+7%3.381+9%3.191+16%
Usd Eps--4.4794.4790%6.941-35%5.806-23%5.115-12%
Usd Free Cash Flow--7300611000.0007300611000.0000%8676315000.000-16%7310407680.0000%6472166220.000+13%
Usd Free Cash Flow Per Share--5.8115.8110%6.903-16%5.8130%5.077+14%
Usd Free Cash Flow To Equity Per Share---0.866-0.8660%2.076-142%0.575-251%1.115-178%
Usd Market Cap119716893056.000-5%125150004000.000125150004000.0000%121008047500.000+3%120595189122.000+4%113975870711.000+10%
Usd Price Per Share95.500-4%99.61099.6100%96.275+3%95.889+4%89.412+11%
Usd Profit--5627880000.0005627880000.0000%8724256200.000-35%7314993360.000-23%6380348400.000-12%
Usd Revenue--44887554000.00044887554000.0000%47304415800.000-5%42237030960.000+6%39415274460.000+14%
Usd Total Gains Per Share--4.4174.4170%7.217-39%5.913-25%4.921-10%
 EOD+4 -4MRQTTM+0 -0YOY+10 -255Y+16 -2010Y+20 -16

3.3 Fundamental Score

Let's check the fundamental score of Sanofi based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1521.320
Price to Book Ratio (EOD)Between0-11.548
Net Profit Margin (MRQ)Greater than00.125
Operating Margin (MRQ)Greater than00.213
Quick Ratio (MRQ)Greater than10.827
Current Ratio (MRQ)Greater than11.267
Debt to Asset Ratio (MRQ)Less than10.412
Debt to Equity Ratio (MRQ)Less than10.704
Return on Equity (MRQ)Greater than0.150.073
Return on Assets (MRQ)Greater than0.050.043
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Sanofi based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.726
Ma 20Greater thanMa 50103.026
Ma 50Greater thanMa 100108.008
Ma 100Greater thanMa 200106.163
OpenGreater thanClose95.750
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Fundamental data was last updated by Penke on 2024-11-06 11:46:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Sanofi earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Sanofi to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 12.5% means that $0.13 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sanofi:

  • The MRQ is 12.5%. The company is making a huge profit. +2
  • The TTM is 12.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ12.5%TTM12.5%0.0%
TTM12.5%YOY18.4%-5.9%
TTM12.5%5Y17.4%-4.9%
5Y17.4%10Y16.1%+1.3%
4.3.1.2. Return on Assets

Shows how efficient Sanofi is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sanofi to the Drug Manufacturers - General industry mean.
  • 4.3% Return on Assets means that Sanofi generated $0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sanofi:

  • The MRQ is 4.3%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.3%TTM4.3%0.0%
TTM4.3%YOY6.7%-2.4%
TTM4.3%5Y5.9%-1.6%
5Y5.9%10Y5.5%+0.4%
4.3.1.3. Return on Equity

Shows how efficient Sanofi is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sanofi to the Drug Manufacturers - General industry mean.
  • 7.3% Return on Equity means Sanofi generated $0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sanofi:

  • The MRQ is 7.3%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 7.3%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ7.3%TTM7.3%0.0%
TTM7.3%YOY11.4%-4.2%
TTM7.3%5Y10.4%-3.1%
5Y10.4%10Y9.7%+0.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Sanofi.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Sanofi is operating .

  • Measures how much profit Sanofi makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sanofi to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 21.3% means the company generated $0.21  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sanofi:

  • The MRQ is 21.3%. The company is operating efficient. +1
  • The TTM is 21.3%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ21.3%TTM21.3%0.0%
TTM21.3%YOY22.2%-0.9%
TTM21.3%5Y20.2%+1.2%
5Y20.2%10Y20.4%-0.2%
4.3.2.2. Operating Ratio

Measures how efficient Sanofi is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.79 means that the operating costs are $0.79 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Sanofi:

  • The MRQ is 0.787. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.787. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.787TTM0.7870.000
TTM0.787YOY0.738+0.049
TTM0.7875Y0.778+0.009
5Y0.77810Y0.789-0.012
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Sanofi.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Sanofi is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 1.27 means the company has $1.27 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Sanofi:

  • The MRQ is 1.267. The company is just able to pay all its short-term debts.
  • The TTM is 1.267. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.267TTM1.2670.000
TTM1.267YOY1.423-0.156
TTM1.2675Y1.460-0.193
5Y1.46010Y1.583-0.122
4.4.3.2. Quick Ratio

Measures if Sanofi is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sanofi to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.83 means the company can pay off $0.83 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sanofi:

  • The MRQ is 0.827. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.827. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.827TTM0.8270.000
TTM0.827YOY0.575+0.253
TTM0.8275Y0.753+0.075
5Y0.75310Y0.931-0.178
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Sanofi.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Sanofi assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sanofi to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.41 means that Sanofi assets are financed with 41.2% credit (debt) and the remaining percentage (100% - 41.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sanofi:

  • The MRQ is 0.412. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.412. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.412TTM0.4120.000
TTM0.412YOY0.410+0.002
TTM0.4125Y0.434-0.022
5Y0.43410Y0.436-0.002
4.5.4.2. Debt to Equity Ratio

Measures if Sanofi is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sanofi to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 70.4% means that company has $0.70 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sanofi:

  • The MRQ is 0.704. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.704. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.704TTM0.7040.000
TTM0.704YOY0.698+0.006
TTM0.7045Y0.775-0.071
5Y0.77510Y0.779-0.004
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Sanofi generates.

  • Above 15 is considered overpriced but always compare Sanofi to the Drug Manufacturers - General industry mean.
  • A PE ratio of 22.24 means the investor is paying $22.24 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sanofi:

  • The EOD is 21.320. Based on the earnings, the company is fair priced.
  • The MRQ is 22.238. Based on the earnings, the company is fair priced.
  • The TTM is 22.238. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD21.320MRQ22.238-0.918
MRQ22.238TTM22.2380.000
TTM22.238YOY13.870+8.367
TTM22.2385Y21.157+1.081
5Y21.15710Y20.535+0.622
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sanofi:

  • The EOD is 16.435. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 17.142. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 17.142. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD16.435MRQ17.142-0.707
MRQ17.142TTM17.1420.000
TTM17.142YOY13.947+3.195
TTM17.1425Y17.014+0.128
5Y17.01410Y18.390-1.376
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Sanofi is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 1.62 means the investor is paying $1.62 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Sanofi:

  • The EOD is 1.548. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.615. Based on the equity, the company is underpriced. +1
  • The TTM is 1.615. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.548MRQ1.615-0.067
MRQ1.615TTM1.6150.000
TTM1.615YOY1.579+0.036
TTM1.6155Y1.717-0.102
5Y1.71710Y1.749-0.032
4.6.2. Total Gains per Share

2.4. Latest News of Sanofi

Does Sanofi still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Sanofi to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2024-11-15
19:19
Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?Read
2024-11-15
11:19
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health DepartmentRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Long-term Assets Other  -5,663,3151,532,034-4,131,281-478,370-4,609,651-746,215-5,355,8666,125,009769,144



6.2. Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets126,464,000
Total Liabilities52,111,000
Total Stockholder Equity74,040,000
 As reported
Total Liabilities 52,111,000
Total Stockholder Equity+ 74,040,000
Total Assets = 126,464,000

Assets

Total Assets126,464,000
Total Current Assets30,655,000
Long-term Assets95,809,000
Total Current Assets
Cash And Cash Equivalents 8,710,000
Short-term Investments 270,000
Net Receivables 11,040,000
Inventory 9,666,000
Other Current Assets 1,239,000
Total Current Assets  (as reported)30,655,000
Total Current Assets  (calculated)30,925,000
+/- 270,000
Long-term Assets
Property Plant Equipment 11,814,000
Goodwill 49,404,000
Long Term Investments 2,666,000
Intangible Assets 73,573,000
Long-term Assets  (as reported)95,809,000
Long-term Assets  (calculated)137,457,000
+/- 41,648,000

Liabilities & Shareholders' Equity

Total Current Liabilities24,194,000
Long-term Liabilities27,917,000
Total Stockholder Equity74,040,000
Total Current Liabilities
Short-term Debt 2,320,000
Short Long Term Debt 2,045,000
Accounts payable 7,328,000
Other Current Liabilities 13,949,000
Total Current Liabilities  (as reported)24,194,000
Total Current Liabilities  (calculated)25,642,000
+/- 1,448,000
Long-term Liabilities
Long term Debt 14,347,000
Capital Lease Obligations 2,030,000
Long-term Liabilities Other 2,841,000
Long-term Liabilities  (as reported)27,917,000
Long-term Liabilities  (calculated)19,218,000
+/- 8,699,000
Total Stockholder Equity
Common Stock2,530,000
Retained Earnings 67,499,000
Accumulated Other Comprehensive Income 4,882,000
Other Stockholders Equity -871,000
Total Stockholder Equity (as reported)74,040,000
Total Stockholder Equity (calculated)74,040,000
+/-0
Other
Capital Stock2,530,000
Cash and Short Term Investments 8,710,000
Common Stock Shares Outstanding 1,256,400
Current Deferred Revenue597,000
Liabilities and Stockholders Equity 126,464,000
Net Debt 9,712,000
Net Invested Capital 90,432,000
Net Working Capital 6,463,000
Property Plant and Equipment Gross 27,442,000
Short Long Term Debt Total 18,422,000



6.3. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-31
> Total Assets 
6,811,000
7,845,000
9,967,000
9,467,757
9,731,632
76,698,065
86,592,434
77,763,240
72,027,324
71,987,000
80,049,000
85,264,000
100,165,000
100,407,000
96,065,000
97,392,000
102,321,000
104,672,000
99,826,000
111,408,000
112,736,000
114,529,000
120,242,000
124,585,000
126,464,000
126,464,000124,585,000120,242,000114,529,000112,736,000111,408,00099,826,000104,672,000102,321,00097,392,00096,065,000100,407,000100,165,00085,264,00080,049,00071,987,00072,027,32477,763,24086,592,43476,698,0659,731,6329,467,7579,967,0007,845,0006,811,000
   > Total Current Assets 
4,877,000
5,403,000
7,671,000
6,565,963
7,024,783
14,439,348
13,111,290
12,160,167
12,572,683
15,403,000
17,532,000
20,043,000
20,791,000
22,901,000
23,926,000
23,437,000
30,680,000
33,108,000
26,386,000
24,647,000
28,936,000
33,786,000
30,653,000
34,111,000
30,655,000
30,655,00034,111,00030,653,00033,786,00028,936,00024,647,00026,386,00033,108,00030,680,00023,437,00023,926,00022,901,00020,791,00020,043,00017,532,00015,403,00012,572,68312,160,16713,111,29014,439,3487,024,7836,565,9637,671,0005,403,0004,877,000
       Cash And Cash Equivalents 
202,000
207,000
123,000
143,898
151,660
1,530,686
1,247,890
1,153,204
1,713,989
4,226,000
4,692,000
6,465,000
4,124,000
6,381,000
8,257,000
7,341,000
9,148,000
10,273,000
10,315,000
6,925,000
9,427,000
13,915,000
10,098,000
12,736,000
8,710,000
8,710,00012,736,00010,098,00013,915,0009,427,0006,925,00010,315,00010,273,0009,148,0007,341,0008,257,0006,381,0004,124,0006,465,0004,692,0004,226,0001,713,9891,153,2041,247,8901,530,686151,660143,898123,000207,000202,000
       Short-term Investments 
2,154,000
2,672,000
4,166,000
2,946,583
3,220,586
957,509
310,706
108,350
83,000
403,000
277,000
51,000
173,000
56,000
59,000
9,000
13,000
31,000
77,000
199,000
426,000
900,000
1,054,000
664,000
270,000
270,000664,0001,054,000900,000426,000199,00077,00031,00013,0009,00059,00056,000173,00051,000277,000403,00083,000108,350310,706957,5093,220,5862,946,5834,166,0002,672,0002,154,000
       Net Receivables 
1,099,000
1,234,000
1,566,000
1,774,430
1,488,012
5,625,548
6,166,840
7,076,067
6,853,899
5,303,000
6,015,000
6,507,000
8,042,000
9,604,000
8,854,000
9,010,000
8,853,000
9,050,000
8,675,000
9,345,000
10,083,000
1,208,000
612,000
374,000
11,040,000
11,040,000374,000612,0001,208,00010,083,0009,345,0008,675,0009,050,0008,853,0009,010,0008,854,0009,604,0008,042,0006,507,0006,015,0005,303,0006,853,8997,076,0676,166,8405,625,5481,488,0121,774,4301,566,0001,234,0001,099,000
       Inventory 
764,000
737,000
805,000
823,366
798,000
3,055,471
3,427,054
3,658,885
3,734,562
3,590,000
4,444,000
13,578,000
16,667,000
16,419,000
15,655,000
16,086,000
15,780,000
16,414,000
16,037,000
17,654,000
19,184,000
18,580,000
19,854,000
20,916,000
9,666,000
9,666,00020,916,00019,854,00018,580,00019,184,00017,654,00016,037,00016,414,00015,780,00016,086,00015,655,00016,419,00016,667,00013,578,0004,444,0003,590,0003,734,5623,658,8853,427,0543,055,471798,000823,366805,000737,000764,000
       Other Current Assets 
424,000
553,000
540,000
336,398
895,666
1,078,488
1,757,853
163,661
82,990
1,708,000
12,840,000
2,000,000
2,401,000
-9,503,000
-8,840,000
-9,000,000
-3,101,000
-2,629,000
-8,641,000
-9,277,000
-9,758,000
83,000
89,000
85,000
1,239,000
1,239,00085,00089,00083,000-9,758,000-9,277,000-8,641,000-2,629,000-3,101,000-9,000,000-8,840,000-9,503,0002,401,0002,000,00012,840,0001,708,00082,990163,6611,757,8531,078,488895,666336,398540,000553,000424,000
   > Long-term Assets 
1,934,000
2,442,000
2,296,000
2,901,794
2,706,848
62,258,717
73,481,144
65,603,073
59,454,641
56,584,000
62,517,000
65,221,000
79,374,000
77,506,000
72,139,000
73,955,000
71,641,000
71,564,000
73,440,000
86,761,000
83,800,000
80,743,000
89,589,000
90,474,000
95,809,000
95,809,00090,474,00089,589,00080,743,00083,800,00086,761,00073,440,00071,564,00071,641,00073,955,00072,139,00077,506,00079,374,00065,221,00062,517,00056,584,00059,454,64165,603,07373,481,14462,258,7172,706,8482,901,7942,296,0002,442,0001,934,000
       Property Plant Equipment 
1,143,000
1,217,000
1,229,000
1,396,101
1,446,723
5,881,523
6,179,505
6,219,120
6,548,001
6,961,000
7,830,000
8,155,000
10,750,000
10,578,000
10,182,000
10,396,000
9,943,000
10,019,000
9,579,000
9,651,000
11,017,000
10,563,000
11,976,000
11,684,000
11,814,000
11,814,00011,684,00011,976,00010,563,00011,017,0009,651,0009,579,00010,019,0009,943,00010,396,00010,182,00010,578,00010,750,0008,155,0007,830,0006,961,0006,548,0016,219,1206,179,5055,881,5231,446,7231,396,1011,229,0001,217,0001,143,000
       Goodwill 
3,000
82,000
141,000
4,784,000
4,788,000
0
30,206,035
28,471,717
27,242,071
28,163,000
29,733,000
31,932,000
38,079,000
38,073,000
37,134,000
39,197,000
39,557,000
40,287,000
40,264,000
44,235,000
44,519,000
44,364,000
48,056,000
49,892,000
49,404,000
49,404,00049,892,00048,056,00044,364,00044,519,00044,235,00040,264,00040,287,00039,557,00039,197,00037,134,00038,073,00038,079,00031,932,00029,733,00028,163,00027,242,07128,471,71730,206,03504,788,0004,784,000141,00082,0003,000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,314,000
4,802,807
4,953,301
4,802,000
5,381,000
5,531,000
5,266,000
7,147,000
7,975,000
9,153,000
2,666,000
2,666,0009,153,0007,975,0007,147,0005,266,0005,531,0005,381,0004,802,0004,953,3014,802,8074,314,00000000000000000
       Intangible Assets 
258,000
319,000
668,000
1,296,039
1,019,535
53,035,504
60,417,135
23,737,670
19,211,905
15,260,000
43,480,000
44,411,000
61,718,000
20,192,000
15,395,000
14,543,000
12,026,000
10,879,000
13,080,000
21,889,000
16,572,000
18,421,000
21,407,000
21,640,000
73,573,000
73,573,00021,640,00021,407,00018,421,00016,572,00021,889,00013,080,00010,879,00012,026,00014,543,00015,395,00020,192,00061,718,00044,411,00043,480,00015,260,00019,211,90523,737,67060,417,13553,035,5041,019,5351,296,039668,000319,000258,000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,097,000
8,819,260
7,718,288
8,849,000
6,598,000
10,199,000
8,717,000
11,346,000
13,455,000
12,856,000
0
012,856,00013,455,00011,346,0008,717,00010,199,0006,598,0008,849,0007,718,2888,819,2607,097,00000000000000000
> Total Liabilities 
3,200,000
3,513,000
4,178,000
3,409,727
3,401,625
40,775,262
39,801,618
31,943,453
27,237,955
26,916,000
31,603,000
31,976,000
43,776,000
42,935,000
39,051,000
41,124,000
44,111,000
46,948,000
41,568,000
52,373,000
53,628,000
51,382,000
51,211,000
51,073,000
52,111,000
52,111,00051,073,00051,211,00051,382,00053,628,00052,373,00041,568,00046,948,00044,111,00041,124,00039,051,00042,935,00043,776,00031,976,00031,603,00026,916,00027,237,95531,943,45339,801,61840,775,2623,401,6253,409,7274,178,0003,513,0003,200,000
   > Total Current Liabilities 
2,217,000
2,258,000
3,006,000
2,548,242
2,587,744
14,994,084
15,408,658
10,278,065
9,684,484
9,345,000
10,965,000
10,087,000
13,564,000
13,898,000
13,958,000
13,032,000
17,808,000
17,629,000
15,457,000
17,376,000
20,387,000
19,280,000
21,295,000
23,974,000
24,194,000
24,194,00023,974,00021,295,00019,280,00020,387,00017,376,00015,457,00017,629,00017,808,00013,032,00013,958,00013,898,00013,564,00010,087,00010,965,0009,345,0009,684,48410,278,06515,408,65814,994,0842,587,7442,548,2423,006,0002,258,0002,217,000
       Short-term Debt 
324,000
291,000
285,000
351,646
314,436
7,382,701
6,420,133
2,445,066
2,210,559
1,833,000
2,866,000
1,565,000
2,940,000
3,812,000
4,176,000
1,538,000
3,436,000
1,764,000
1,275,000
2,633,000
4,815,000
2,999,000
3,452,000
4,451,000
2,320,000
2,320,0004,451,0003,452,0002,999,0004,815,0002,633,0001,275,0001,764,0003,436,0001,538,0004,176,0003,812,0002,940,0001,565,0002,866,0001,833,0002,210,5592,445,0666,420,1337,382,701314,436351,646285,000291,000324,000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,590,000
1,456,569
3,453,519
1,764,000
1,275,000
2,633,000
4,554,000
2,767,000
3,183,000
4,174,000
2,045,000
2,045,0004,174,0003,183,0002,767,0004,554,0002,633,0001,275,0001,764,0003,453,5191,456,56914,590,00000000000000000
       Accounts payable 
642,000
667,000
717,000
596,559
655,869
2,762,612
3,190,647
3,008,029
2,753,082
2,791,000
8,099,000
8,424,000
10,404,000
9,948,000
9,757,000
11,363,000
13,259,000
14,472,000
13,839,000
14,402,000
15,274,000
15,427,000
17,397,000
18,834,000
7,328,000
7,328,00018,834,00017,397,00015,427,00015,274,00014,402,00013,839,00014,472,00013,259,00011,363,0009,757,0009,948,00010,404,0008,424,0008,099,0002,791,0002,753,0823,008,0293,190,6472,762,612655,869596,559717,000667,000642,000
       Other Current Liabilities 
1,251,000
1,300,000
1,994,000
1,600,037
1,617,439
4,848,771
5,797,877
4,824,970
4,720,843
4,721,000
5,445,000
98,000
220,000
138,000
25,000
131,000
1,113,000
1,393,000
343,000
341,000
298,000
32,000
127,000
425,000
13,949,000
13,949,000425,000127,00032,000298,000341,000343,0001,393,0001,113,000131,00025,000138,000220,00098,0005,445,0004,721,0004,720,8434,824,9705,797,8774,848,7711,617,4391,600,0371,994,0001,300,0001,251,000
   > Long-term Liabilities 
983,000
1,255,000
1,172,000
861,485
813,881
25,781,178
24,392,960
21,665,388
17,553,471
17,571,000
20,638,000
21,889,000
30,212,000
29,037,000
25,093,000
28,092,000
26,303,000
29,319,000
26,111,000
34,997,000
33,241,000
32,102,000
29,916,000
27,099,000
27,917,000
27,917,00027,099,00029,916,00032,102,00033,241,00034,997,00026,111,00029,319,00026,303,00028,092,00025,093,00029,037,00030,212,00021,889,00020,638,00017,571,00017,553,47121,665,38824,392,96025,781,178813,881861,4851,172,0001,255,000983,000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,679,000
17,924,026
14,319,070
12,504,000
11,785,000
12,990,000
11,895,000
11,205,000
10,954,000
10,835,000
0
010,835,00010,954,00011,205,00011,895,00012,990,00011,785,00012,504,00014,319,07017,924,02614,679,00000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,993,000
1,743,286
1,686,577
1,359,000
1,475,000
4,744,000
2,334,000
6,092,000
7,730,000
6,226,000
0
06,226,0007,730,0006,092,0002,334,0004,744,0001,475,0001,359,0001,686,5771,743,2861,993,00000000000000000
> Total Stockholder Equity
3,578,000
4,304,000
5,768,000
6,040,877
6,311,744
35,548,062
46,601,690
45,600,057
44,612,414
44,866,000
48,188,000
53,097,000
56,219,000
57,338,000
56,885,000
56,120,000
58,049,000
57,554,000
58,089,000
58,876,000
58,934,000
63,001,000
68,681,000
73,144,000
74,040,000
74,040,00073,144,00068,681,00063,001,00058,934,00058,876,00058,089,00057,554,00058,049,00056,120,00056,885,00057,338,00056,219,00053,097,00048,188,00044,866,00044,612,41445,600,05746,601,69035,548,0626,311,7446,040,8775,768,0004,304,0003,578,000
   Common Stock
1,462,000
1,463,000
1,464,000
1,466,621
1,463,397
2,820,888
2,800,576
2,719,349
2,736,621
2,631,000
2,637,000
2,622,000
2,682,000
2,653,000
2,649,000
2,639,000
2,611,000
2,584,000
2,508,000
2,495,000
2,508,000
2,518,000
2,527,000
2,522,000
2,530,000
2,530,0002,522,0002,527,0002,518,0002,508,0002,495,0002,508,0002,584,0002,611,0002,639,0002,649,0002,653,0002,682,0002,622,0002,637,0002,631,0002,736,6212,719,3492,800,5762,820,8881,463,3971,466,6211,464,0001,463,0001,462,000
   Retained Earnings Total Equity0000000000000000000000000
   Accumulated Other Comprehensive Income 
-15,000
-30,000
-17,000
-160,099
-403,367
-3,013,423
2,672,241
-692,529
-3,195,468
-4,419,000
-3,936,000
-1,152,000
-960,000
52,732,000
52,090,000
51,576,000
52,922,000
53,441,000
52,297,000
52,938,000
52,572,000
56,688,000
62,156,000
68,185,000
4,882,000
4,882,00068,185,00062,156,00056,688,00052,572,00052,938,00052,297,00053,441,00052,922,00051,576,00052,090,00052,732,000-960,000-1,152,000-3,936,000-4,419,000-3,195,468-692,5292,672,241-3,013,423-403,367-160,099-17,000-30,000-15,000
   Capital Surplus 0000000000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
2,131,000
2,871,000
4,321,000
2,974,219
3,179,296
39,347,851
41,128,873
43,573,237
7,146,765
46,654,000
49,487,000
51,627,000
54,497,000
1,953,000
2,146,000
1,905,000
2,516,000
-49,948,000
-49,578,000
-49,663,000
-47,926,000
-56,354,000
-59,015,000
-64,297,000
-871,000
-871,000-64,297,000-59,015,000-56,354,000-47,926,000-49,663,000-49,578,000-49,948,0002,516,0001,905,0002,146,0001,953,00054,497,00051,627,00049,487,00046,654,0007,146,76543,573,23741,128,87339,347,8513,179,2962,974,2194,321,0002,871,0002,131,000



6.4. Balance Sheets

Currency in EUR. All numbers in thousands.




6.5. Cash Flows

Currency in EUR. All numbers in thousands.




6.6. Income Statements

Currency in EUR. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue43,070,000
Cost of Revenue-16,572,000
Gross Profit26,498,00026,498,000
 
Operating Income (+$)
Gross Profit26,498,000
Operating Expense-17,315,000
Operating Income9,183,0009,183,000
 
Operating Expense (+$)
Research Development6,725,000
Selling General Administrative10,656,000
Selling And Marketing Expenses-
Operating Expense17,315,00017,381,000
 
Net Interest Income (+$)
Interest Income584,000
Interest Expense-1,094,000
Other Finance Cost-226,000
Net Interest Income-284,000
 
Pretax Income (+$)
Operating Income9,183,000
Net Interest Income-284,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)7,153,00011,213,000
EBIT - interestExpense = 8,089,000
7,002,000
6,494,000
Interest Expense1,094,000
Earnings Before Interest and Taxes (EBIT)9,183,0008,247,000
Earnings Before Interest and Taxes (EBITDA)12,959,000
 
After tax Income (+$)
Income Before Tax7,153,000
Tax Provision-2,203,000
Net Income From Continuing Ops9,162,0004,950,000
Net Income5,400,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses33,887,000
Total Other Income/Expenses Net-2,030,000284,000
 

Technical Analysis of Sanofi
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sanofi. The general trend of Sanofi is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sanofi's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sanofi.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 102.35 < 102.35 < 112.05.

The bearish price targets are: 95.45 > 92.55 > 87.72.

Tweet this
Sanofi Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sanofi. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sanofi Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sanofi. The current macd is -3.02337541.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sanofi price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Sanofi. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Sanofi price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Sanofi Daily Moving Average Convergence/Divergence (MACD) ChartSanofi Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sanofi. The current adx is 21.00.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Sanofi shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Sanofi Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sanofi. The current sar is 109.68.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Sanofi Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sanofi. The current rsi is 32.73. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Sanofi Daily Relative Strength Index (RSI) ChartSanofi Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sanofi. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sanofi price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Sanofi Daily Stochastic Oscillator ChartSanofi Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sanofi. The current cci is -129.15505152.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Sanofi Daily Commodity Channel Index (CCI) ChartSanofi Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sanofi. The current cmo is -43.30742485.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Sanofi Daily Chande Momentum Oscillator (CMO) ChartSanofi Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sanofi. The current willr is -99.6410214.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Sanofi Daily Williams %R ChartSanofi Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sanofi.

Sanofi Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sanofi. The current atr is 1.77106937.

Sanofi Daily Average True Range (ATR) ChartSanofi Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sanofi. The current obv is 1,050,565.

Sanofi Daily On-Balance Volume (OBV) ChartSanofi Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sanofi. The current mfi is 19.89.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Sanofi Daily Money Flow Index (MFI) ChartSanofi Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sanofi.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-10STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-12STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-21ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-26MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-09MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-06MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Sanofi Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sanofi based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.726
Ma 20Greater thanMa 50103.026
Ma 50Greater thanMa 100108.008
Ma 100Greater thanMa 200106.163
OpenGreater thanClose95.750
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Sanofi with someone you think should read this too:
  • Are you bullish or bearish on Sanofi? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sanofi? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sanofi

I send you an email if I find something interesting about Sanofi.


Comments

How you think about this?

Leave a comment

Stay informed about Sanofi.

Receive notifications about Sanofi in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.